Shukui Qin

机构：China Pharmaceutical University, Fudan University, Nanjing General Hospital of Nanjing Military Command, Jinyintan Hospital, Zhongshan Hospital, Jiangsu Cancer Hospital, Nanjing Jiangning Hospital, PLA Army Engineering University, Jinling Institute of Technology · ORCID：0000-0002-3414-2790

发表论文 186 篇 · 总被引 17089 次 · h-index 42

代表论文

• Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study (2025 · The Lancet · 被引 267)
• Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study (2025 · Journal of Hepatology · 被引 68)
• Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis (2024 · Gastric Cancer · 被引 14)
• First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study (2025 · Advances in Therapy · 被引 9)
• First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649. (2025 · Journal of Clinical Oncology · 被引 7)
• Analysis of clinically actionable alterations in baseline tumor versus plasma samples in participants of the TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. (2025 · Journal of Clinical Oncology · 被引 4)